SCHEMBL1996281

SCHEMBL1996281

CN1CCOc2ccc3[nH]ccc3c2C1

nearest known ligand 0.40

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 2/20 0.40
KDM4E B2RXH2 2/20 0.39
MAPT P10636 1/20 0.39
CHRNA7 P36544 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NUDT1 P36639 1/20 0.35
HTR1D P28221 5/20 0.35
ADRB1 P08588 1/20 0.34
HTR6 P50406 1/20 0.34
HTT P42858 1/20 0.34
HTR1B P28222 3/20 0.33
MAOA P21397 1/20 0.33
KIF11 P52732 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2002050 0.78 CREBBP (0.46) CREBBPKDM4EMAPTHTR1D
SCHEMBL1978270 0.76 MEN1 (0.41) CREBBPHTR1DHTR6HTR1B
SCHEMBL1997743 0.74 CREBBP (0.43) CREBBP
SCHEMBL6092206 0.73 HTR1D (0.47) HTR1DHTR6HTR1B
SCHEMBL4266397 0.72 HTR1D (0.34) CREBBPHTR1DHTR6HTR1B
Trifluoroacetic Acid SCHEMBL1995893 0.68 CREBBP (0.35) CREBBP
SCHEMBL3900178 0.67 ADRA2A (0.39) CREBBPKDM4EADRB1HTT
SCHEMBL2000040 0.67 CREBBP (0.40) CREBBPKDM4E
SCHEMBL2043007 0.67 OXTR (0.38) HTR1DADRB1HTR6HTR1B
SCHEMBL6109246 0.64 HTR1D (0.38) HTR1DHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960374-B2 e.g. 2,5-methylene-9-(phenylsulfonyl)-1,2,3,4,5,9-hexahydro[1,5]oxazocino[3,2-e]indole; serotonin receptors antagonist or partial agonist; metabolic diseases, e.g. obesity, insulin resisitance, type 2 diabetes, eating disorders; antidepressant, anxiolytic agent; cosmetics PROXIMAGEN LIMITED (GB) 2011-06-14 US disclosed
EP-2091953-A1 8-SULFONYL-L, 3, 4, 8-TETRAHYDR0-2H- [1, 4]OXAZEPINO [6, 7-E]INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 RECEPTOR LIGANDS BIOVITRUM AB (publ) (SE) 2009-08-26 EP disclosed
US-20080176829-A1 Compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-07-24 US disclosed
WO-2008054288-A1 8-SULFONYL-L, 3, 4, 8-TETRAHYDR0-2H- [1, 4] OXAZEPINO [6, 7-E] INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 RECEPTOR LIGANDS BIOVITRUM AB (PUBL) (SE) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176829-A1 Compounds HTR6, HTR1B, HTR1A CREBBP 2723/4885KDM4E 3829/4885MAPT 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.